HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer |
| |
Authors: | Mads Hald Andersen Rikke B Soerensen Jürgen C Becker Per thor Straten |
| |
Institution: | 1. Center for Cancer Immunotherapy (CCIT), Department of Hematology, Herlev University Hospital, 2730, Herlev, Dk, Denmark 2. Department of Dermatology, University of Würzburg, D-97080, Würzburg, Germany
|
| |
Abstract: | Recently, it was described that an HLA-A24 restricted peptide derived from the survivin splice variant survivin-2B can be
recognized by CD8(+) cytotoxic T-cells. The identification of an HLA-A24 epitope is critical for survivin-based immunotherapy
as HLA-24 is the most frequent HLA allele in Asia. Consequently, this survivin-2B epitope is already a target in a clinical
study in patients with advanced or recurrent colorectal cancer expressing survivin. However, the splice variant survivin-2B
has been described to be pro-apoptotic, and is only expressed at low levels in most malignant tissues. Furthermore, survivin-2B
expression are significantly decreased in later tumor stages and inversely correlated with tumor differentiation and invasion.
Consequently, survivin is a more general vaccination candidate than the splice variant survivin-2B. Here, we on the basis
of spontaneous immune responses in HLA-A24+ cancer patients describes that a HLA-A24-restricted survivin epitopes does indeed
exist. Consequently, this epitope is an attractive target for the ongoing survivin-based peptide immunotherapy against cancer. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|